New York, June 06, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today announced that company CEO, Michael Nelson, will present at the 2016 BIO International Convention on Tuesday, June 7 at 2pm at the New York Pavilion.
“We are pleased to update the life sciences and investment communities on several important company milestones that Intrommune has reached in 2016,” said CEO Michael Nelson. “On March 1st, the USPTO issued a key patent for our oral mucosal immunotherapy (OMIT) technology platform. On April 25th, data from a 24-person clinical investigation demonstrating the efficacy and adherence benefits of OMIT was published. These milestones set the stage for further clinical development of INT-301.”
Intrommune’s lead product, INT-301, is being developed for the treatment of peanut allergies. Peanut allergy is a potentially deadly disease which affects 1.5 million children at an estimated cost of more than $6 billion per year to families in the United States. There is currently no treatment for this condition.
About Oral Mucosal Immunotherapy
Food allergies affect an estimated 15 million Americans, including 6 million children, and over 220 million people worldwide. Allergen-specific immunotherapy is the only treatment modality that targets the root cause of the disease, consistently exposing the allergy sufferer’s immune system to small amounts of allergen proteins to desensitize them to the allergens over time. There is currently no commercially-available allergy immunotherapy product for food allergies. Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic extracts to the areas of the oral cavity with the greatest potential for allergy desensitization. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and ease of long-term patient adherence.
About Intrommune Therapeutics
Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. Intrommune’s lead product, INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. OMIT is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from this life-altering condition.
Danya Glabau, PhD Director of Medical Affairs Intrommune Therapeutics email@example.com
Source: Intrommune Therapeutics